ArticleClinical ophthalmology (Auckland, N.Z.)2024
Visual and Refractive Outcomes After Bilateral Implantation of a New Toric Intraocular Lens.
Article in Clinical ophthalmology (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical performance of a segmented refractive multifocal IOL: visual outcomes, rotational stability, and the role of higher-order aberrations.International ophthalmology · 2026Article
- Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of an Enhanced Monofocal IOL: An Exploratory Comparison of Achieved Mini-Monovision and Bilateral Emmetropia.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the clinical outcomes of a new FDA approved toric aspheric hydrophobic acrylic intraocular lens. Patients and Methods: This is a single surgeon, single-arm, on-label, non-randomized, prospective observational study. Thirty patients underwent bilateral cataract surgery (60 eyes) with placement of a Clareon™ Toric IOL in each eye. The Barrett Universal II formula and Barrett toric calculator were used to determine the IOL power and toric axis. Endpoints included binocular and monocular best corrected distance visual acuity (BCDVA), binocular and monocular best uncorrected distance visual acuity (UCDVA), binocular uncorrected intermediate visual acuity (UCIVA), manifest refraction and patient Satisfaction Survey (IOLSAT) results over a 3 month follow-up. Results: The postoperative mean LogMAR visual acuity for binocular BCDVA and UCDVA were each 0.01±0.05. The monocular BCDVA and UCDVA were 0.04±0.06 and 0.08±0.08 respectively. The mean refractive cylinder improved from 1.87±1.12D to 0.43±0.25D with 78.3% within 0.50D. The mean refractive spherical equivalent (MRSE) was 0.008 ± 0.30 D (range -0.75 to +0.63, 93.3% results within ± 0.5D). Patient surveys showed 96.7% gained distance spectacle independence and 96.7% would recommend this lens to friends or family members. Conclusion: The Clareon Monofocal Toric IOL is effective in astigmatism correction and significantly improved uncorrected distance visual acuity. High spectacle independence for distance vision and high overall satisfaction were achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.